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The Treatment of Chronic
Myocardial Ischemia?*
JONATHAN ABRAMS, MD, FACC
Albuquerque, New Mexico
Antianginal agents. The mechanism or mechanisms of
action of antianginal drugs are an appropriate area of inquiry
for investigators. The three standard agents used in the
treatment of chronic effort angina-nitrates, beta-adrenergic
blocking agents and calcium channel antagonists-have dif-
fering effects on the peripheral vasculature, coronary artery
bed and myocardial performance. All of these drugs, how-
ever, reduce myocardial work at rest and exercise, usually
through a lowering of one or more of the factors that affect
left ventricular wall tension. Beta-blockers lower heart rate,
particularly during activity, whereas the nitrates and the
dihydropyridines (nifedipine) increase heart rate; verapamil
and diltiazem have a modest negative chronotropic action.
Blood pressure is lowered by all three classes of drugs but
nitrate tolerance attenuates their hypotensive actions. Cor-
onary artery vasodilation occurs with nitrate or calcium
channel antagonist administration. All three groups of drugs
have been shown to enlarge coronary stenosis caliber.
Nevertheless, the benefit of antianginal drugs in enhancing
coronary blood supply remains an unproved hypothesis as
an important mechanism for relief of angina in patients who
receive a nitrate or calcium channel blocker, whereas this
action cannot be implicated for the beta-blockers.
Potential role of angiotensin-converting enzyme (ACE)
inhibitors in angina pectoris. The ACE inhibitors are a
remarkable class of drugs that are highly effective in the
treatment of hypertension and congestive heart failure.
There is an ample hypothetic rationale for the relief of
myocardial ischemia with these agents. The ACE inhibitors
decrease arterial vascular resistance and systemic blood
pressure and reduce myocardial oxygen consumption (1-3).
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They may have a coronary artery dilating action through
inhibition of local and circulating angiotensin II and they
increase coronary artery flow in certain circumstances
(1,4,5). Thus, it is reasonable to administer ACE inhibitors in
an effort to reduce myocardial work during exercise and
possibly increase coronary blood supply, actions that should
alleviate angina. In addition, it is conceivable that direct
myocardial and coronary artery ACE inhibition might be
beneficial to patients with coronary artery disease (1,6,7).
These drugs have sympatholytic action; there is no reflex
tachycardia after ACE inhibitor administration.
Several preliminary studies have sought to employ ACE
inhibitors for angina. In hypertensive patients with anginal
chest pain, these agents have shown some promise in
alleviating determinants of myocardial ischemia (8,9). How-
ever, the record of ACE inhibitors in stable angina in the
absence of hypertension has been mixed (9-16). Some
previous trials (8,11,12), including our own (10), have not
shown a benefit. The well designed study by Klein et al. (17)
in this issue of the Journal, utilizing the ACE inhibitor
benazepril, reaches a comparable conclusion, that there is
no efficacy for benazepril in effort angina. Thus, it seems
advisable to discontinue the use of ACE inhibitors for the
therapy of chronic stable angina in normotensive subjects.
ACE inhibitors in silent myocardial ischemia: the present
study. There is a tantalizing suggestion in the study of Klein
et al. (17) that the ACE inhibitors may reduce asymptomatic
episodes of ischemia, although benazepril had no effect on
exercise-induced angina or ST segment depression. There is
experimental support for anti-ischemic activity of these
agents (3-7,13,14). Blockade of the conversion of angioten-
sin I to angiotensin II should decrease coronary artery
vasoconstriction and improve coronary blood flow, particu-
larly in patients with episodic coronary vasoconstriction or
an abnormal vasomotor response to exercise. In addition,
the sympatholytic effects of these drugs might decrease
coronary vascular tone, possibly preventing or reversing
episodes of coronary constriction that could be responsible
for some episodes of asymptomatic ischemia. It is possible
that drug therapy with ACE inhibitors might prove ineffec-
tive when compared with placebo in rigidly controlled exer-
cise test protocols in patients with angina yet reduce the
number of episodes of ambulatory silent ischemia, which are
typically less intense than induced ischemia and are more
likely to be caused by transient decreases in coronary blood
supply.
In my judgment, the conclusion of Klein et al. (17) that
ACE inhibitor therapy might be effective in silent ischemia is
premature. The data for a reduction of silent ischemic
attacks by benazepril represent only a trend toward im-
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out for only 24 h. whereas most experts currently recom-
mend 2:48 h for baseline and intervention studies. The
day-to-day frequency of silent myocardial ischemia is not
known but it may be quite variable (18).
In any case. the likelihood that clinicians will select an
ACE inhibitor for treatment of silent ischemia is very low.
The currently available conventional antianginal agents are
effective in reducing ambulatory myocardial ischemia. al-
though they do not appear to completely abolish the epi-
sodes. Similarly. there is little current enthusiasm for aggres-
sive treatment of silent ischemia in itself; this attitude seems
appropriate given the methodologic difficulties in its accurate
detection and quantification and the uncertain benefit of
initiating therapy solely for silent episodes of ST segment
depression.
Metoprolol OROS in angina pectoris: the present study.
The study of Klein et al. (17) is an exemplary investigation in
many ways and is an excellent model for studies of angina. It
represents classic antianginal study design and employs a
relatively large group of patients who are carefully catego-
rized. All patients were documented to have not only ob-
structive coronary artery disease. but also active myocardial
ischemia as determined by the presence of four anginal
attacks in the preceding month. (It is unclear whether or not
this was during therapy.) In addition. the patients were
carefully withdrawn from all antianginal medications. so that
the experimental drugs were evaluated without potential
competing or attenuating effects. or both. of other anti-
ischemic agents. Careful treadmill exercise test procedures
were utilized.
The long-acting OROS formulation of metoprolol em-
ployed in this protocol was very effective. Exercise tests
were performed at least 24 h after the drug was given.
documenting antianginal efficacy over a sustained period.
The heart rate and blood pressure data also indicate that
beta-adrenergic blockade persisted throughout the 24 h
period.
Conclusions. This is a well designed. traditional antiangi-
nal drug study. The results indicate convincingly that meto-
prolol OROS is a beneficial antianginal formulation that has
an extraordinarily long duration of action. There is no
evidence that ACE inhibition plays a role in relief of stable
effort angina pectoris. There is a suggestion that ACE
inhibitors may reduce the number of episodes of silent
myocardial ischemia. but the data base is small and the
results are of uncertain significance. This hypothesis should
stimulate further work utilizing ACE inhibitors in investiga-
tions of coronary vasomotor tone and silent ischemia. How-
ever. the current clinical relevance of this concept appears to
be limited.
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